8-K 1 helix8k_11052002.txt REPORT FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 ____________________________ Date of report (Date of earliest event reported) October 31, 2002 ---------------- HELIX BIOMEDIX, INC. -------------------------------------------------------------------------------- (Exact Name of Registrant as Specified in Charter) Delaware 33-20897-D 91-2099117 -------------------------------------------------------------------------------- (State or Other Jurisdiction (Commission IRS Employer of Incorporation) File Number) Identification No.) 22122 20th Ave. SE #148, Bothell, WA 98021 -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code (425) 402-8400 --------------- Item 5. Other Events and Regulation FD Disclosure On October 31, 2002, Helix BioMedix, Inc. ("Helix") signed a letter of intent with Nu Skin International, Inc. (Nu Skin) to enter into a developmental agreement with Nu Skin for the use of a Helix peptide in a Nu Skin acne treatment product. Helix received a technology access fee upon signing the letter of intent. Helix will also receive royalties depending on the performance of the technology. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HELIX BIOMEDIX, INC. Date: November 5, 2002 /s/ R. Stephen Beatty ---------------- -------------------------------- Name: R. Stephen Beatty Title: President and Chief Executive Officer